In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0025 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Jeremy Clark und 1 weiteren Autor:innen. Beteiligte Einrichtung: Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.). Hauptthemen laut MEDLINE: COVID-19, Fluvoxamine.
Abstract (Originalsprache)
SOURCE CITATION: McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329:296-305. 36633838.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.).
Zitieren
APA
Clark, J., & Tong, S. Y. C. (2023). In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery. Annals of Internal Medicine. https://doi.org/10.7326/j23-0025
Vancouver
Clark J, Tong SYC. In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery. Annals of Internal Medicine. 2023. doi:10.7326/j23-0025
BibTeX
@article{Clark2023,
author = {Clark, Jeremy and Tong, Steven Y C},
title = {In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0025}
}
EUVIMED